Atrium Therapeutics, Inc. (RNA) stock
Close on Nov 13, 2026Market cap $128.46MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $128.46M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.63
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Book value per share
- $12.03
- Diluted shares
- 17M
Trading
- Previous close
- $7.50
- Open
- $7.71
- Day's range
- $7.47 – $7.83
- Volume
- 195,173
- Average volume (20 days)
- 224,665
- Index membership
- Russell 2000 (since Mar 2026), Russell 3000 (since Feb 2026)
- Beta (5 years)
- 1.33
- 52-week range
- $7.47 – $73.06
- RSI (14 days)
- 32.7
- Volatility (1 year)
- 90.6%
- Relative volume
- 0.79×
- WACC
- 11.7%
On 2 of our idea lists: Net-nets, More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | RNA | S&P 500 | Difference | RNA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -3.1% | -3.0% | −0.1 pts | ||
| 3 months | -39.1% | -2.8% | −36.3 pts | ||
| Year to date | -89.6% | +11.5% | −101.1 pts | ||
| 1 year | -89.4% | +13.5% | −102.9 pts |
Two years at a glance
Fiscal years 2024 to 2025, USD
Press releases
Releases Atrium Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- News
- News
- Results
Atrium Therapeutics stock: common questions
What is Atrium Therapeutics's stock price?
RNA closed at $7.51 on Nov 13, 2026, up 0.13% on the day. Over the past 52 weeks it traded between $7.47 and $73.06.
What is Atrium Therapeutics's market cap?
Atrium Therapeutics was worth $128.46M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
Does Atrium Therapeutics pay a dividend?
No. Atrium Therapeutics has not paid a cash dividend over the last twelve months.
How has RNA stock performed over the past year?
Including dividends, RNA returned -89.4% over the past year, against +13.5% for the S&P 500.
How many RNA shares are sold short?
4M shares were sold short at the latest FINRA report, 22.61% of the float, or 16.1 days of average trading volume.
Who are Atrium Therapeutics's competitors?
Companies most similar to Atrium Therapeutics by business, industry and size include LLY, JNJ, ABBV, MRK, AZN.
See a number that looks wrong?